产品详情
所在位置: 首页> 产品目录> 一抗>
查看大图

  • 产品名称：anti-FLT4antibody(Fms-RelatedTyrosineKinase4)

  • 产品型号：
  • 产品厂商：半导体
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
anti-FLT4antibody(Fms-RelatedTyrosineKinase4)
详情介绍：
Immunogen Purified His-tagged VEGFR3 protein was used to produced this monoclonal antibody.
Clone 818CT12-1-1
Isotype IgG2a
Purification This antibody is purified through a protein G column, followed by dialysis against PBS.
Alternative Name VEGFR3 (FLT4 Antibody Abstract)
Background Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in ***** lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades, isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.

Synonyms: FLT4,VEGFR3, Vascular endothelial growth factor receptor 3, Vascular endothelial growth factor receptor 3, Fms-like tyrosine kinase 4, Vascular endothelial growth factor receptor 3, Tyrosine-protein kinase receptor FLT4
NCBI Accession NP_002011, NP_891555
UniProt P35916
Pathways RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling
Application Notes WB: 1:2000
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer Purified monoclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative Sodium azide
Precaution of Use WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
Supplier Images
Western Blotting (WB) image for anti-Fms-Related Tyrosine Kinase 4 (FLT4) antibody (ABIN1882290) VEGFR3 Antibody (ABIN1882290) western blot analysis in 293 and A549 cell line lysates...
Product cited in: Irrthum, Karkkainen, Devriendt, Alitalo, Vikkula: "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase." in: American journal of human genetics, Vol. 67, Issue 2, pp. 295-301, 2000 (PubMed).

Galland, Karamysheva, Pebusque, Borg, Rottapel, Dubreuil, Rosnet, Birnbaum: "The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor." in: Oncogene, Vol. 8, Issue 5, pp. 1233-40, 1993 (PubMed).

Pajusola, Aprelikova, Korhonen, Kaipainen, Pertovaara, Alitalo, Alitalo: "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines." in: Cancer research, Vol. 52, Issue 20, pp. 5738-43, 1992 (PubMed).

Galland, Karamysheva, Mattei, Rosnet, Marchetto, Birnbaum: "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene." in: Genomics, Vol. 13, Issue 2, pp. 475-8, 1992 (PubMed).